Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure
- PMID: 1824669
- DOI: 10.1213/00000539-199102000-00002
Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure
Abstract
We determined the pharmacokinetics and duration of action of a bolus dose of doxacurium (15 micrograms/kg) in 27 patients anesthetized with isoflurane and nitrous oxide. Nine patients had normal renal and liver functions and were undergoing a variety of surgical procedures, nine were undergoing cadaveric kidney transplantation because of end-stage renal disease, and nine were undergoing cadaveric liver transplantation because of end-stage hepatocellular disease. Plasma concentrations of doxacurium were measured for 6 h after administration using a sensitive and specific capillary gas chromatographic assay. Plasma concentration versus time data were analyzed by a noncompartmental method based on statistical moments. Neuromuscular blockade was assessed by measuring the electromyographic evoked response of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve. The degree of neuromuscular blockade after doxacurium administration was described as the percent of control of the first train-of-four response. The pharmacokinetic variables were (normal vs hepatic failure vs renal failure, respectively): volume of distribution at steady state (220 +/- 110 vs 290 +/- 60 vs 270 +/- 130 mL/kg [mean +/- SD]), plasma clearance (2.7 +/- 1.6 vs 2.3 +/- 0.4 vs 1.2 +/- 0.7 mL.kg-1.min-1), mean residence time (95.2 +/- 57 vs 129.4 +/- 30 vs 270 +/- 210 min), and elimination half-life (99 +/- 54 vs 115 +/- 31 vs 221 +/- 156 min). Plasma clearance and mean residence time differed significantly between patients with renal failure and control patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.Drugs. 1991 Oct;42(4):673-89. doi: 10.2165/00003495-199142040-00009. Drugs. 1991. PMID: 1723368 Review.
-
Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure.Br J Anaesth. 1992 Dec;69(6):580-5. doi: 10.1093/bja/69.6.580. Br J Anaesth. 1992. PMID: 1334687
-
The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide.Anesthesiology. 1989 Jan;70(1):7-12. doi: 10.1097/00000542-198901000-00004. Anesthesiology. 1989. PMID: 2536254
-
Clinical pharmacology of doxacurium chloride (BW A938U) in children.Anesth Analg. 1988 Apr;67(4):303-6. Anesth Analg. 1988. PMID: 2965532
-
Clinical pharmacokinetics of the newer neuromuscular blocking drugs.Clin Pharmacokinet. 1999 Mar;36(3):169-89. doi: 10.2165/00003088-199936030-00001. Clin Pharmacokinet. 1999. PMID: 10223167 Review.
Cited by
-
Doxacurium. A review of its pharmacology and clinical potential in anaesthesia.Drugs. 1991 Oct;42(4):673-89. doi: 10.2165/00003495-199142040-00009. Drugs. 1991. PMID: 1723368 Review.
-
Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.Drugs. 1992 Aug;44(2):182-99. doi: 10.2165/00003495-199244020-00003. Drugs. 1992. PMID: 1382013 Review.
-
The use of muscle relaxants in the intensive care unit.Can J Anaesth. 1992 Nov;39(9):949-62. doi: 10.1007/BF03008345. Can J Anaesth. 1992. PMID: 1451224 Review.
-
Adverse effects of nondepolarising neuromuscular blocking agents. Incidence, prevention and management.Drug Saf. 1994 Jun;10(6):420-38. doi: 10.2165/00002018-199410060-00002. Drug Saf. 1994. PMID: 7917072 Review.
-
Selecting neuromuscular-blocking drugs for elderly patients.Drugs Aging. 2003;20(2):125-40. doi: 10.2165/00002512-200320020-00004. Drugs Aging. 2003. PMID: 12534313 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous